Diabetes Therapy
Dipeptidyl peptidase IV inhibitors show promise as antidiabetic agents
Published in Obesity and Diabetes Week, September 12th, 2005
"A number of new approaches to diabetes therapy are currently undergoing clinical trials, including those involving stimulation of the pancreatic beta cell with the gut-derived insulinotropic hormones (incretins), GIP and GLP-1. The current review focuses on an approach based on the inhibition of dipeptidyl peptidase IV (DP IV), the major enzyme responsible for degrading the incretins in vivo," investigators in Canada and Germany report.
"The rationale for this approach was that blockade of incretin degradation would increase their physiological actions, including the stimulation...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Epidemiology
Prevalence of type 2 diabetes in obese Argentinean children reported - Diabetes Pathogenesis
Beta-cell function across spectrum of glucose tolerance examined - Diabetes Pathogenesis
FFA receptor links hyperinsulinemia and impaired glucose homeostasis - Diabetes Therapy
Insulin pump provides better glycemic control than daily injections - Insulin Resistance
FOXC2 overexpression prevents diet-induced insulin resistance - Adipose Tissue
Site-specific changes in adipose tissues in obesity investigated - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
